By [Journalist Name]
Published: Special Feature
Main Facts: The Double Life of Michael Polansky
In an industry famously dominated by outsize egos, performative public relations, and a relentless pursuit of viral attention, Michael Polansky cuts a remarkably unassuming figure. Seated on a leafy patio outside a popular bakery in Mill Valley—an affluent enclave roughly 15 miles north of San Francisco—the bespectacled entrepreneur sports a fresh-faced, dark-haired look flecked with gray. With his approachable demeanor, he could easily pass for a tenured young professor.
Yet Polansky occupies one of the most eccentric intersections in modern business. By day—and often by night—he leads a striking double life. On one hand, he moves effortlessly through the upper echelons of global celebrity as the creative, business, and romantic partner to Stefani Germanotta, globally renowned as Lady Gaga. On the other hand, he serves as the co-founder and CEO of Outer Biosciences, an under-the-radar artificial intelligence and biology startup that has quietly spent years accomplishing a milestone previously thought impossible: keeping living human tissue alive and viable outside the body for over a month.
While the public has long speculated about Polansky’s high-profile relationship, his scientific endeavors have remained shrouded in secrecy. Operating with a lean 19-person team based primarily just outside Cambridge, Massachusetts, Outer Biosciences has sidestepped the traditional noise of Silicon Valley to build a closed-loop system marrying real human biology with machine learning.
Chronology: From Applied Math to Silicon Valley and Biotech
Polansky’s path to the bleeding edge of biotechnology was neither linear nor planned. Growing up in Minnesota, he cultivated an analytical mind that led him to Harvard University, where he studied applied mathematics and computer science, graduating in 2006.
Following graduation, Polansky spent three years at Bridgewater Associates, the notoriously intense Connecticut-based hedge fund. He recalls his time there as “a very unique place” and a “really good experience,” though it ultimately failed to ignite a long-term passion. “It wasn’t a place I was going to wake up and be excited about every day,” he notes over coffee.
The pivot that redirected his life westward began through a stroke of geographic coincidence. At a 2009 wedding in Minnesota, Polansky crossed paths with a former childhood neighbor who happened to be working as an assistant to tech luminary Sean Parker. Knowing Parker was looking for fresh talent and eager to make his own move to the West Coast, Polansky secured a dinner meeting in New York. The two hit it off immediately; Polansky quit Bridgewater the next day and relocated to San Francisco.
The Founders Fund and Philanthropic Years
Polansky initially landed as a principal at Founders Fund during its formative era when it was operated by its four original visionary partners: Peter Thiel, Sean Parker, Luke Nosek, and Ken Howery. Sharing an office with fellow young principal Brian Singerman, Polansky describes the tenure as foundational.
When Parker later became liquid in his Facebook stock and decided to establish his own dedicated family office, he brought Polansky along. For years, Polansky managed Parker’s multifaceted business ventures, private investments, and philanthropic initiatives. Notably, he helped stand up the prestigious Parker Institute for Cancer Immunotherapy, where he maintains his role as executive director to this day. That chapter continued until the onset of the COVID-19 pandemic, which he notes shifted his life trajectory into entirely new realms.
Entering the Orbit of Lady Gaga
That monumental shift was catalyzed by Germanotta. Polansky met the pop superstar in late 2019 at one of Parker’s birthday parties. Charmingly, the introduction was engineered by Germanotta’s mother, Cynthia Germanotta, president of the Born This Way Foundation, whom Polansky had befriended through his philanthropic endeavors.
“She had said, you know, for months and months, ‘I want to set you up with my daughter,’” Polansky recalls. “I was like, I think you’re making fun of me.”
She wasn’t. When their respective mothers later met, Polansky laughs, “it all made perfect sense.” Today, the two mothers are close friends, and Polansky and Germanotta operate in a deeply integrated personal and professional partnership.
Supporting Data: The Mechanics of Outer Biosciences
While Polansky is quick to credit his decade alongside Sean Parker in cancer immunotherapy for sparking his journey into the life sciences—a field he entered “accidentally” when it was still considered fringe—Outer Biosciences represents a distinct scientific gamble.
Co-founded in 2022 by Polansky (CEO), Kyung-Jin Jang (Chief Scientist), Chris Hinojosa (CTO), and Stanley King (Chief Business Officer), the company was born out of profound frustration. Historically, the pace of innovation in biology and chemistry has lagged woefully behind software. Why? Because ethical boundaries prevent direct, unvarnished experimentation on living human beings.
To bridge this gap, scientists have long relied on flawed proxies: animal models, simplified cell cultures, and lab-grown organoids. None of these accurately replicate the complex behavior of a living human organ.
Sourcing and Sustaining Living Human Tissue
Outer Biosciences bypassed synthetic engineering altogether. Instead, the company sources human skin—predominantly tissue discarded during elective plastic surgeries—via vetted non-profit and commercial biobanks and brokers. These suppliers operate under strict institutional review board (IRB) oversight and documented donor consent, principally partnering with organizations like the National Disease Research Interchange (NDRI) and the Cooperative Human Tissue Network (CHTN). Both entities receive federal funding from the NIH and the National Cancer Institute, though they remain independently operated.
Polansky emphasizes that Outer Biosciences pays these suppliers strictly on a cost-recovery basis rather than making outright commercial purchases of tissue. It took the startup roughly two years to build out this regulatory pipeline and establish the rigorous protocols required to receive tissue within hours of surgery while it remains metabolically active.
Every sample arrives entirely de-identified, stripped upstream of names, contact information, and personal identifiers. Once inside the lab, a proprietary support system developed by Polansky’s team continuously supplies the tissue with vital nutrients while systematically removing metabolic waste.
Defying Industry Norms: 30 Days Out
In standard laboratory settings, living skin tissue typically degrades within a matter of days. While adequate for testing acute toxicity, this truncated lifespan makes it impossible to observe slower biological processes such as collagen remodeling, pigmentation shifts, or barrier repair—phenomena that dermatologists know take weeks to unfold.
Outer Biosciences’ proprietary system defies this norm. The company can successfully keep human tissue alive for up to a month. According to Polansky, the sustained tissue retains its "day-zero architecture and preserves its day-zero epidermal, stromal, and immune-associated molecular programs." In layman’s terms: 30-day-old tissue maintained by the company bears an uncanny resemblance to fresh tissue harvested on day one.
This extended window unlocks unprecedented observational capabilities. For instance, researchers can induce controlled UVB damage (sunburn) in living tissue, subsequently tracking the ensuing stress, inflammatory, and recovery responses over several weeks. Rather than artificially "healing" the skin, scientists can watch injury and biological adaptation unfold in real-time.
The Closed-Loop AI Integration
The true proprietary value of Outer Biosciences, however, lies in how its components interlock. The startup utilizes a closed, self-enforcing data pipeline:
- AI Prediction: A proprietary machine-learning model predicts which untested chemical compounds are likely to yield beneficial effects on specific skin functions.
- Empirical Testing: Those candidate compounds are administered directly to the living-tissue system.
- Model Feedback: The empirical results—whether validating or invalidating the AI’s initial hypothesis—are immediately fed back into the model, drastically sharpening subsequent predictions.
Initially, the startup relied on a labor-intensive, brute-force approach, mining scientific literature and partnering with the National Cancer Institute to test natural compounds from extreme environments. That early phase yielded only a couple of leads over 18 months. With the AI model integrated, the company now generates a viable candidate roughly every six weeks, boasting six active leads in its pipeline alongside dozens of logged "hits."
Official Responses and Strategic Roadmap
As Outer Biosciences steps out of the shadows, Polansky is methodical in how he frames the company’s market positioning. Unlike traditional AI startups that gorge themselves on scraped internet data, Polansky points out that "there is no biology internet to scrape." The proprietary data Outer Biosciences generates simply does not exist anywhere else.
Regulatory Routes and Commercialization
Because Outer Biosciences focuses primarily on discovering cosmetic ingredients rather than pharmaceutical drugs, the path forward bypasses the grueling FDA approval process required for over-the-counter therapeutics. Instead, the commercialization pipeline involves:
- Securing standardized industry nomenclature for newly discovered ingredients.
- Executing safety testing under stringent guidelines set by the OECD (Organization for Economic Co-operation and Development), an international body whose member nations mutually accept properly executed studies across more than 40 countries.
Rather than building a direct-to-consumer brand, Outer Biosciences plans to license or sell its finished ingredients to established beauty and pharmaceutical giants who will formulate them into consumer products—serums, creams, and treatments—under their own brand names. Four of the company’s six current leads are already tracking toward commercialization.
Simultaneously, the startup generates revenue through high-value collaborative research partnerships. These include a major pharmaceutical alliance studying why specific cancer drugs induce severe skin rashes, as well as consumer beauty brands validating their own product-development hypotheses against Outer Biosciences’ datasets.
Financial Footing and Industry Landscape
To date, Outer Biosciences has raised approximately $23 million in venture capital. Early backers include Wing Ventures, Initialized Capital, and Polansky’s own investment firm, Hawktail.
While the company is not alone in the race to revolutionize preclinical testing—notable competitors like Philadelphia-based Vivodyne have raised close to $80 million building lab-grown human organ tissue, while others pursue "organ-on-a-chip" models—Polansky remains remarkably unfazed. The market is vast, and the defensive moat provided by exclusive, real-tissue empirical data offers unique insulation.
Furthermore, Outer Biosciences’ infrastructure is remarkably cost-effective compared to the exorbitant compute demands of training massive Large Language Models (LLMs). Notably, all of the company’s AI computational work runs strictly on-premise, not in the cloud. "We don’t want the data in the cloud," Polansky states flatly.
Implications: A New Frontier in Dermatology and Beyond
The implications of Polansky’s dual worlds—balancing the high-octane theatrical logistics of Lady Gaga’s global tours (which he compares to managing a "200-person startup that travels around the world every day") with the meticulous rigors of cellular biology—point toward a profound shift in how consumer products and medical treatments are conceptualized.
By proving that complex human tissue can survive, react, and regenerate in a laboratory setting for a full month, Outer Biosciences is effectively accelerating the timeline of dermatological discovery by years. The ability to test cosmetic and therapeutic compounds against actual human biology—rather than simplified animal models or petri-dish cell cultures—promises safer, more effective formulations with drastically reduced trial-and-error cycles.
For Polansky, the transition from stealth mode to public engagement marks a liberating milestone. "Trying to do this in private is hard," he reflects as the Mill Valley bakery staff begin flipping chairs onto tables at closing time. "We kind of want to start working in public now."
Whether Outer Biosciences ultimately evolves into a standalone ingredient titan, licenses its groundbreaking discoveries en masse, or pivots toward a single breakout pharmaceutical compound remains unwritten. But as the startup expands its product-development team and brings its years of quiet labor to light, Michael Polansky is proving that true innovation often happens away from the spotlight—even when your partner is one of the most famous people on the planet.
Disclaimer: When you purchase through links in our articles, we may earn a small commission. This does not affect our editorial independence.
